DR. DERRICK WONG M.D. NPI 1194941104

NPI Details

DR. Derrick Wong, M.D. is a hematology and oncology internal medicine in Mountain View, CA with 25 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Derrick Wong, M.D. NPI is 1194941104. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF CALIFORNIA, GEFFEN SCHOOL OF MEDICINE
Graduation Year:2001

The provider's business location address is:

701 E EL CAMINO REAL
MOUNTAIN VIEW, CA
ZIP 94040-833
Phone: (650) 934-7600

The NPI 1194941104 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, tocilizumab, 1 mg (HCPCS:J3262)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1459)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, infliximab, excludes biosimilar, 10 mg (HCPCS:J1745)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Bcg live intravesical instillation, 1 mg (HCPCS:J9030)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion, normal saline solution, 250 cc (HCPCS:J7050)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or (HCPCS:G2212)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Instillation of anti-cancer drug into bladder (HCPCS:51720)
• Collection of blood sample from implanted device (HCPCS:36591)
• Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes (HCPCS:99223)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Drawing of blood for a medical problem (HCPCS:99195)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)

The enumeration date for this NPI number is 4/18/2007 and was last updated on 12/2/2011.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: